South African Government


South Africa has received 2.8 million Pfizer vaccine doses from the United States as part of a donation that is set to boost the country’s vaccination rollout campaign.

Acting Health Minister Mmamoloko Kubayi was joined by Deputy Minister, Dr Joe Phaahla and the Chief of Mission at the US Embassy in South Africa, Todd Haskell, in accepting the consignment at OR Tambo International Airport on Saturday. 

According to the Department of Health, the arrival of this first batch is part of a donation from the US government.

The initiative is part of the collaboration between the African Vaccine Acquisition Trust (AVAT), COVAX, and the US government, with the African Union Member States set to receive about 25 million COVID-19 vaccine doses to enhance coverage across the continent, and vaccinate at least 60% of the African population. 

“The next batch will arrive on Tuesday to conclude the 5.6 million doses. The donation will contribute to the country’s expanded vaccination programme, which is fast gaining momentum to reach more people,” the Health Department said on Twitter.

The department said these life-saving vaccines arrive at a time when the country gears to vaccinate those aged between 18 and 34 from September.

“By the time we open for people between the ages of 18 and 34 to be vaccinated from the 1st of September 2021, we will be able to respond to the demand that this cohort will generate,” Kubayi said last week during a media briefing. 

The department believes the donation contributes to the security of supply to meet the demands to reach government's milestones to inoculate the majority of the population soon. 

In addition, about 1 454 900 Johnson&Johnson vaccines are expected to be transported to various sites on Tuesday.

Distributed by APO Group on behalf of South African Government.

Send us your press releases to pressrelease.zawya@refinitiv.com


© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.